Published • loading... • Updated
Rasonque: FDA Approves Pancreatic Cancer Pill
The oral treatment was cleared after trials showed a 13.1-month median survival, compared with 8.5 months for patients on chemotherapy.
- On Wednesday, the FDA approved Daraxonrasib, a pancreatic cancer drug sold under the brand name Rasonque that nearly doubled median survival to 13.2 months from 6.7 months with chemotherapy alone.
- Revolution Medicines created the drug to block RAS protein forms that drive tumor growth in stage 4 pancreatic cancer patients who have failed prior chemotherapy or cannot tolerate it.
- The once-daily pill costs roughly $39,800 for a one-month supply, though eligible commercially insured patients can access it for $0 with copay assistance, addressing affordability concerns.
- Patients receiving the drug through FDA Expanded Access Programs or clinical trials report significant tumor shrinkage within weeks, with side effects including acne, rash, and mouth sores manageable with medical support.
- Experts caution the drug is not a cure but can prolong survival and provide hope; trials are underway testing whether it prevents relapse in advanced-stage patients.
Insights by Ground AI
25 Articles
25 Articles
FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
·Mona Vale, Australia
Read Full Article
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The oral, once-daily RAS(ON) multi-selective inhibitor is approved for adults with metastatic pancreati
·Sioux Falls, United States
Read Full Article
Coverage Details
Total News Sources25
Leaning Left5Leaning Right1Center6Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 42%
C 50%
Factuality
To view factuality data please Upgrade to Premium
